Lawsuits allege Olympus endoscopes and duodenoscopes had design defects that trapped bacteria — transmitting serious infections, including antibiotic-resistant CRE superbugs, between patients.
Olympus manufactures the majority of the endoscopes and duodenoscopes used in U.S. procedures. Duodenoscopes — used in ERCP procedures — contain an elevator mechanism that proved extremely difficult to clean and disinfect between patients.
Outbreak investigations linked contaminated scopes to transmission of carbapenem-resistant Enterobacteriaceae (CRE) and other multi-drug-resistant infections at hospitals across the country. Regulators required design changes, and Olympus has issued multiple recalls — including a 2025 recall of the MAJ-891 suction valve component.
Claims allege patients contracted serious infections after procedures with contaminated scopes — and that design defects, inadequate cleaning protocols, and delayed corrective action put patients at risk. Olympus previously paid substantial settlements and a federal deferred-prosecution agreement over outbreak-related conduct.
Infection claims against scope manufacturers continue following multiple outbreaks, design changes, and recalls — including the 2025 suction-valve recall. Cases are evaluated individually based on the procedure, device, and documented infection.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Olympus Scope campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Olympus Scope Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.